Valproate is the preferred mood stabilizer for this patient with bipolar II disorder, chronic kidney disease, and no thyroid.
Given the combination of CKD and absence of thyroid function, valproate emerges as the safest and most practical first-line mood stabilizer, as lithium is contraindicated due to nephrotoxicity risk and the patient's inability to use thyroid supplementation to manage lithium-induced hypothyroidism.
Why Not Lithium
Lithium would typically be considered for bipolar disorder given its strong evidence base, but it is absolutely the wrong choice here:
Nephrotoxicity is dose-dependent and cumulative 1, 2, 3. Long-term lithium use significantly increases the risk of chronic kidney disease (HR 2.54-3.65 for definite CKD) 2. In patients with pre-existing CKD, lithium accelerates progression toward end-stage renal disease 4, 3.
Lithium causes nephrogenic diabetes insipidus by downregulating aquaporin-2 in collecting duct cells, impairing urinary concentrating ability 5, 3. This patient already has compromised renal function and cannot tolerate further tubular damage.
The patient has no thyroid, which is critical because lithium commonly causes hypothyroidism. Without a functioning thyroid, you cannot manage this predictable adverse effect with supplementation—the patient is already thyroid-dependent.
CKD reduces lithium clearance, necessitating dose reductions that may compromise efficacy while still risking toxicity 3.
Why Valproate
Valproate (divalproex sodium) is the optimal choice because:
No significant renal toxicity: Unlike lithium, valproate does not cause progressive kidney damage 6. It has been successfully used in patients with renal failure on hemodialysis 6.
Hepatic metabolism: Valproate is primarily metabolized by the liver, not excreted unchanged by the kidneys, making it safer in CKD.
Established efficacy in bipolar II: Valproate is effective for mood stabilization and prevention of both manic and depressive episodes.
Practical dosing in CKD: While protein binding may be altered in severe CKD, valproate can be titrated to clinical effect with monitoring of free drug levels if needed 6.
Practical Implementation
Start valproate 250-500 mg twice daily, then titrate upward based on clinical response and tolerability 6:
- Target therapeutic range: 50-125 mcg/mL (total valproate level)
- Monitor liver function tests at baseline, 2 weeks, 1 month, then every 3-6 months
- Check CBC for thrombocytopenia risk
- In CKD, consider checking free valproate levels if clinical response is unclear
Avoid carbamazepine and other anticonvulsants as first-line options because anticonvulsants as a class show increased risk of CKD in bipolar patients (HR 2.30 for definite CKD with ≥60 prescriptions) 2.
Alternative Considerations
If valproate fails or is not tolerated:
- Lamotrigine may be considered, particularly for bipolar II depression, though it requires slow titration and has less robust antimanic efficacy
- Atypical antipsychotics (quetiapine, lurasidone, cariprazine) can be used, but many carry metabolic and cardiovascular risks that compound CKD-related morbidity 1
- Avoid MAOIs, which showed the highest kidney disorder risk in large observational studies (HR 2.66) 1
Critical Monitoring
Given this patient's CKD, establish baseline and ongoing monitoring:
- Renal function: Check serum creatinine and eGFR every 3-6 months per KDIGO guidelines 7
- Electrolytes: Monitor potassium, particularly if on RAS inhibitors for CKD management 7
- Drug levels: Valproate trough levels to ensure therapeutic dosing without toxicity
Common Pitfalls to Avoid
- Do not start lithium "just to try it" in a patient with pre-existing CKD—the risk-benefit ratio is unfavorable 4, 2, 3
- Do not assume all mood stabilizers are equally safe in CKD—lithium and potentially anticonvulsants carry specific renal risks 1, 2
- Do not forget that polypharmacy increases kidney disorder risk—the hazard ratio escalates with each additional psychotropic class 1